Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Yervoy
Yervoy
Bristol-Myers Squibb and Gritstone Oncology Announce Collaboration to Evaluate Novel Immunotherapy Approach in Advanced Solid Tumors
CP Wire
Thu, 07/19/18 - 10:05 am
Bristol-Myers Squibb
Gritstone Oncology
Opdivo
Yervoy
GRANITE-001
cancer
Opdivo Gains New Approval in Combination with Yervoy
CP Wire
Wed, 07/11/18 - 11:32 am
Opdivo
Yervoy
Bristol-Myers Squibb
metastatic colorectal cancer
BMY Is Rapidly Advancing Its First-Line NSCLC Research Program
Market Realist
Mon, 05/28/18 - 01:26 pm
Bristol-Myers Squibb
Opdivo
non-small cell lung cancer
Yervoy
EMA Validates Bristol-Myers Squibb’s Variation Application for Opdivo Plus Yervoy Combination for Treatment of First-Line Metastatic Non-Small Cell Lung Cancer
CP Wire
Thu, 05/3/18 - 11:16 am
Bristol-Myers Squibb
Opdivo
Yervoy
metastatic non-small cell lung cancer
EMA
Europe
EMA Validates Bristol-Myers Squibb’s Variation Application for Opdivo Plus Yervoy Combination for Treatment of First-Line Metastatic Non-Small Cell Lung Cancer
Thu, 05/3/18 - 09:24 am
Bristol-Myers Squibb
non-small cell lung cancer
Opdivo
Yervoy
Bristol's Opdivo-Yervoy duo snares a quick FDA nod in first-line kidney cancer
Fierce Pharma
Mon, 04/16/18 - 11:36 pm
Bristol-Myers Squibb
Opdivo
Yervoy
kidney cancer
Merck, Bristol-Myers cancer drugs both beat expectations, but Merck beats them a little more
CNBC
Mon, 04/16/18 - 09:46 am
Merck
Bristol-Myers Squibb
Keytruda
Opdivo
Yervoy
non-small cell lung cancer
AACR
With big Keytruda and Opdivo data coming at AACR, analyst hands Merck the early edge
Fierce Pharma
Fri, 04/13/18 - 12:55 pm
Merck
Bristol-Myers Squibb
Keytruda
Opdivo
Yervoy
AACR
Bristol-Myers' Opdivo-Yervoy combo scores again at FDA, this time in colorectal cancer
Fierce Pharma
Tue, 03/27/18 - 09:56 pm
Bristol-Myers Squibb
Opdivo
Yervoy
FDA
colorectal cancer
More Questions Than Answers For Bristol-Myers
Forbes
Tue, 02/6/18 - 09:18 am
Bristol-Myers Squibb
Opdivo
Yervoy
Bristol claims victory in crucial immunotherapy trial, but results raise some questions
Stat
Mon, 02/5/18 - 11:52 am
Bristol-Myers Squibb
Opdivo
Yervoy
advanced lung cancer
Bristol-Myers surges 5.6% on advanced lung cancer trial results, Q4 earnings
Marketwatch
Mon, 02/5/18 - 08:33 am
Bristol-Myers Squibb
earnings
Opdivo
Yervoy
advanced lung cancer
Opdivo-Yervoy combo 'encouraging' in colorectal cancer
Biopharma Dive
Mon, 01/22/18 - 10:54 am
Opdivo
Yervoy
Bristol-Myers Squibb
colorectal cancer
Yervoy inventor’s oncology startup Pionyr gets $62M for tumor-fighting tech
Endpoints
Wed, 12/13/17 - 11:11 am
Yervoy
oncology
Pionyr
Positive times for Bristol-Myers Squibb
GoinPharma
Sun, 10/22/17 - 09:47 am
Bristol-Myers Squibb
Opdivo
Yervoy
‘Going big’: Merck launches frontline PhIII lung cancer study for Keytruda/Yervoy combo
Endpoints
Fri, 10/6/17 - 11:41 am
Merck
lung cancer
Keytruda
Yervoy
Bristol-Myers Squibb
The Top Cancer Immunotherapies Expected to Reach $1 Billion in Sales in 2017
Motley Fool
Mon, 09/18/17 - 10:53 am
cancer
cancer immunotherapies
Opdivo
Bristol-Myers Squibb
Keytruda
Merck
Yervoy
Exelixis, Inc. and Bristol-Myers Squibb Co. Gear Up for Round 2 of the Kidney Cancer Drug Battle Royale
Motley Fool
Thu, 09/14/17 - 06:56 pm
Exelixis
Bristol-Myers Squibb
kidney cancer
Cabometyx
Opdivo
Yervoy
With Yervoy-beating data, Opdivo poised to fight melanoma's return after surgery
Fierce Pharma
Mon, 09/11/17 - 09:52 am
Yervoy
Opdivo
Bristol-Myers Squibb
melanoma
Opdivo combo shows early survival benefit in kidney cancer
BioPharma Dive
Fri, 09/8/17 - 09:34 am
Opdivo
Yervoy
Bristol-Myers Squibb
kidney cancer
Pages
« first
‹ previous
1
2
3
4
5
6
7
next ›
last »